-

: 2759 : 0
: 978 : 0
..
: 1606 : 0
-
: 1748 : 0
: 3334 : 0

 - -

 -

   bodyalex

 - e-mail

 

 -

 LiveInternet.ru:
: 29.09.2010
:
:
: 439

:

(0)

, 11 2011 . 08:57 +
_ [ + !]



 

 
 
 

 

,   , . , .


, , , , , . , , ( ) .


  – 2 , 1-2 . . . , .


  , . , , , , , - . .
.


- .

 

:

 

 

"":
1 - .
2 -
...
98 - . . ..
99 -
100 -

:  
(0)

:

, 21 2011 . 09:18 +
_ [ + !]

:

4188600_y_tr3 (432x229, 10Kb)

– , . …

? «», « »? ? , ? ? , ? ? , « », « »…

...

:  
(0)

( 8 )

, 21 2011 . 09:16 +
[ + !]

( 8 )


556b1c73ab3eb6de5f33cfd0b0a (500x400, 37Kb)



( 8 )

**



" ":

1 - ,
2 - !!!
...
98 - .
99 -
100 - .




" ":

1 -
2 - .
...
98 -
99 -
100 -




"":

1 - .. - ( MP3) -
2 - .. - ( MP3) -
...
98 -
99 - . . , .
100 - )



:  
(0)

:)

, 11 2010 . 14:32 +
Ingreed [ + !]

:)

 

...

«»!

, . — 13.10.2005
- , . , .
 

 
1.
 
. , , , . . , .
 
. , , .
 
2. ,
 
( ). . 6 .
 
. .
 

 
3.
 
. . , . , . -. 3 - 4 .
 
. , , .
 
4.
 
, . . .
 
. , , .
 
5.
 
, ( ), . - . 5 - 6 .
 
. . .
 

 
6.
 
, . . , .
 
. . .
 
7.
 
, , . -. 6 .
 
. , .
 
8.
 
-.
 
. , , .
 

 
9.
 
, ( ). . , . .
 
. , .
 
10.
 
, , , , . , .
 
, , , . , . . , , , , , . , .

:  
(0)

, 11 2010 . 14:31 +
ToKiTo4Ka [ + !]




, , . , :

1. , .

2. . . .

3. , . .

 

4. .


         .
.

?

. , . , . , .

?

- !

- , , -, ?

- , - . - , . - , . .

 


:  
(0)

, 11 2010 . 14:31 +
-_ [ + !]



. : - ? : ! : , - - . , , : . , , , . ? , . , ( ). ""?! , - - , , , .

  • , , . , , , , ( 1). - . , , . - , , . , , - 6 ( ) 7 ( - ).

  • 1

...

:  
(0)

- ?

, 05 2010 . 11:57 +
- [ + !]

- ?

, - , , - - . 

, . , , ( ). , .

, , , . !

, . , , . , , , . 


:  
(0)

, 11 2010 . 18:42 +
. , , . , , , , , , , , . , , . .
20-25 .
. , , , , .
, . . , ; , , , . .. , .
, , , : ( ), , :
1) ;
2) ;
3) ;
4) ;
5) , ;
6) , , .
. , , , . , , .
, , FDA , . , , , , .
. (Commission on Dietary Supplement Labels). . , , , . DS . :
- ;
- - ;
.
.. (, ), (, , , ) . , , - , , .
, , , , , . ( , ).
, . , :
, ;
, ;
( ).
. . , (borderline medicinal products).
, . , , , , . .
, , , , , , , , ( , ). , , , , . , , , , , , , .
, , . :
- . , - , . .
- , , ( ).
- , , , , , . , . , .
- , .
- , , , . , . , ( , ). , , . , .
- . , , , , , . , , , , . : , , , .

:  
(0)

?

, 11 2010 . 06:03 +
, . : , , . , , , . , .


, . , , . , , .


: . , - , . , . , , , :



30% ; 10% .

, - .

- . ( , , )

- . , . - ( ). , . , 30 .

2000 , .

. . -, ( ), . -, . , , . , , - .

, ( ). , , .

, , - .




- , . - 17- . , , , , ( ), . . , , , , ( ). , - , . : , .


. , , (1).


, . .


(), . , , , , , , , (2).


, , , (3), .


, , , , . - , - . , . - . , , . , , .

:  
(0)

, ,

, 09 2010 . 09:24 +
. , , , . - , , . ? , , , . , , , . , , , - , , . , , - , . , ( , - ?), - . , , .
, - . , , , , - , . , . , , . .
? - . , . ? , , , . , , , ( , ). - , . , . - , , . , . , , .
-. , , . , , - . , ( ) - . , , . , , . . - , .
, . , . - . . , 5 :
" , (, ) . , , - . 100 !
, , . . , , , . , . . , , , . , , .
, , . , . , , . , .
, ! , , , . . , ."

- !

1. , - , -, - . - .
2. , , , . !

:  
(0)

, 09 2010 . 09:17 +
. , , , , , . . , -. . , . . . . ? , , . . , .

, , . , , , - . , , .
, , - .

, , , , . , , --, , 300 . , , , . , 150 , 140 . , -, . , . , . , , , , . , .

, . , . , . , , , , , , . , . - , , , , . ? . , . , . , , , .

, , , . , . , , , , , , , . , , , . , , , . , , , . , .

. , , , . . , , .
. , . , , , . , .

, . , . , . , , , , . . , , . , . 70 , 50 , , . ? . - , . - , , , . , , , J - .

:  
(0)

-

, 08 2010 . 19:12 +
- - , - . - , : , - . ? 46 -, c ...
- ! , , , - . , . , .

?
. , : ( ) 30 60 . , ( 50 , ) ( ... 58 !). , . , - . , . - , - . , , . - 30 , - . - , , 20- , . . . , ( , , ), . , . , , . - ( !) , 94 , . .-
30 ?
- , . 1-2% . , . . 30, , 10-20%. , , : . . - ( , , , ).-
?
- . - . , .
- , ?
- ( 50-55 , , , ), - , . , , - . , . .
- , . , . . . , , , , , .
- , . - . , . , , , - -. ( , , ), . , , .-
. ?
- . , . . - . , . . - ?
- . . , . , . . , , . - . 3-5 . - , , ?
- . . , . , , , .

, , . , , . - , , - . - . , . , , . .-
? , , .
- . 20- . , , . , . - .-
?
- . - , . . , , . . , . , , , , . , . , , . , , . . . , , . . , . , , , . -, , . . , ( ). , . . , . - . . , ( ). , . , , , . , , ... .

:  
(0)

, 08 2010 . 18:50 +
 (520x486, 64Kb)
, , , , , . .



, . , .

, , , , , , . , . .

. . . , (, ) , (, ).

, . 30% . , , 66% . , , .

, , . , .

. . . . , , , , .

, , , .

( 100%), , , D, E, K.

(, ).

, , , . , , , , ..

.

:  
(0)

, 08 2010 . 18:38 +
- , "" . . , , , , , .

, , . , "" , , .

, , .

, 30-40 . , , , , - ADAM PADAM, . , 15-25% 30-50 , 30-38% 50-, 50-80% 60 .

:

. :

*
*
*
*
*

. :

* , ,
* ("")
*
*
*
*

. :

*
*
*
*
*
*

. :

*
*
*
*
*
*
*

, .

, .

- , , ; ( 1 ) - , , ; : , , .

http://akmed.spb.ru/testosteron/testosteron.html

:  
(0)

Male Hormone Restoration

, 08 2010 . 18:36 +
As men age, they begin to experience changes in their bodies. Abdominal fat increases and muscle mass decreases. They also experience a distressing decline in their sex drive. At the same time, the risk of serious health conditions such as depression and heart disease rises. While most conventional physicians (and some members of the lay media) dismiss these woes as signs of natural aging, there is often an underlying and identifiable cause of these symptomsthe gradual decline of important sex hormones, especially testosterone.

Too often, men who have problems related to a low testosterone level are advised to treat only the symptoms of their conditions (such as taking antidepressant and/or cholesterol-lowering drugs). Fortunately, progressive physicians, along with the Life Extension Foundation, now recognize the connection between hormones and the diseases of aging. Restoration of youthful hormone levels is associated with optimal sexual function, energy, and vitality, while declining hormone levels correlate with many age-related conditions, including high blood pressure, atherosclerosis, diabetes, loss of muscle and bone mass, and fatigue (Shores MM et al 2004).

Factors That Affect Testosterone Levels

Testosterone, which is abundantly produced during puberty, is responsible for the development of secondary sexual characteristics and has profound effects throughout the body. Testosterone receptors are found in virtually all body tissues, so levels of testosterone affect the function of most organ systems. For example, testosterone causes growth of facial and body hair in skin cells, increased fiber size and strength in muscle cells, and maturation of the external genitalia. The effects of testosterone on the central nervous system are also well-known (Okun MS et al 2004). Testosterone governs such behaviors as aggression, risk taking, and territoriality. It is now recognized as an important factor in mitigating depression (King JA et al 2005).

As with all sex hormones, testosterone is part of a cascade that begins with cholesterol, the building block for hormones. Pregnenolone, the master hormone, is produced directly from cholesterol. In turn, dehydroepiandrosterone (DHEA; a precursor to testosterone), testosterone (and its metabolites), and estrogen (and its metabolites) are produced from pregnenolone. Both testosterone and estrogen are produced by enzymatic reactions from DHEA. This ubiquitous molecule is the steroid found in highest quantities in humans. Changes in the supply of DHEA (and/or changes in the levels of the enzymes that convert DHEA to the sex hormones) can have powerful effects on sex hormonedependent systems.

As men age, a number of changes occur that reduce the testosterone level available to the body and that alter the ratio between testosterone and the chief female hormone, estrogen. This condition is now referred to as partial androgen deficiency of aging men (Harman SM 2005).

One of the most important factors that affect testosterone levels of aging men is an enzyme called aromatase, which is found in fat tissue. This enzyme is responsible for converting testosterone into estrogen, thus altering the ratio of estrogen to testosterone (Steiner MS et al 2003). Men who have excessive body fat, especially abdominal fat, are likely to have increased estrogen levels caused by aromatase activity and a dramatically increased estrogen level compared to testosterone. An increased estrogen level has been linked, in turn, to a host of disorders, including decreased insulin sensitivity and blood glucose problems. Some studies suggest that there is an association between a low testosterone level, insulin resistance, an elevated estrogen level, and increased body fat in aging men (Phillips GB 1993).

This relationship between low testosterone and obesity has been described as the hypogonadal/obesity cycle. In this cycle, a low testosterone level leads to an increase in abdominal fat, which leads to increased aromatase activity, which leads to further conversion of testosterone to estradiol, which further reduces testosterone and increases the tendency toward abdominal fat (Cohen PG 1999).

The effect of sex hormones on tissues is also affected by the level of sex hormonebinding globulin (SHBG). Sex hormones circulate in the bloodstream in very small quantities as free molecules. The bulk of sex hormones are bound to SHBG, which is a specialized carrier protein (Nankin HR et al 1986). Hormones bound to carrier molecules are inactive, so the amount of SHBG has an important impact on the degree to which tissues respond to sex hormone levels (Misao R et al 1999; Zmuda JM et al 1993; Dambe JE et al 1983; Van Look PF et al 1981). Nutritional status and the levels of other hormones are among the factors that determine levels of SHBG.

Aging men who have an androgen deficiency experience both an increase in aromatase activity and an elevation in SHBG production. The net result is to increase the ratio of estrogen to testosterone and lower the total testosterone level (Killinger DW et al 1987; Kley HK et al 1980a,b). Finally, it is important that aging men also strive for optimal liver function. The liver is responsible for removing excess estrogen and SHBG, so any compromise in liver function (such as that caused by heavy alcohol consumption, for example) can exacerbate hormonal imbalances.

Effects of Age-Related Decline in Testosterone Levels

The exact causes of the age-related reduction in testosterone levels is not known; it is probably the result of a combination of factors, including increased body fat (and therefore increased aromatase activity), oxidative damage to tissues responsible for the production of testosterone, and declining levels of precursor molecules such as DHEA. The results of the decline, however, are strikingly apparent.

Nervous system effects. Low testosterone levels have been associated with depression and other psychological disorders (Barrett-Connor E et al 1999b; Rabkin JG et al 1999; Schweiger U et al 1999; Seidman SN et al 1999; Moger WH 1980). In addition, many conventional antidepressants suppress libido. Some experts recommend that patients whose reduced libido is caused by taking antidepressants undergo testing to have their testosterone levels checkedand that they get supplemental treatment if necessary. Others suggest that testosterone therapy might reduce the need for the antidepressants themselves (Goldstat R et al 2003; Morley JE 2003). Feelings of well-being are often reported with testosterone treatment (Carnahan RM et al 2004; Dunning TL et al 2004; Orengo CA et al 2004; Wright JV et al 1999).

Cognition and alertness are also governed in part by testosterones effects on the central nervous system (Cherrier MM et al 2004; Cherrier MM et al 2001; Janowsky JS et al 2000). Low testosterone levels have been shown to correlate with lower scores on various psychometric tests (Moffat SD et al 2002; Barrett-Connor E et al 1999a; Janowsky JS et al 1994). Similar effects have been reported in men taking androgen-deprivation therapy for prostate cancer (Salminen EK et al 2004). Testosterones ability to protect nerve cells against a variety of toxins, including oxidative stress (Ahlbom E et al 2001) and the Alzheimers protein beta-amyloid (Zhang Y et al 2004; Hammond J et al 2001), may explain the low testosterone levels found in men who have neurodegenerative diseases (Hogervorst E et al 2004; Okun MS et al 2004; Ready RE et al 2004).

Sexual enjoyment and function. Falling levels of free testosterone diminish sexual desire, as well as pleasure and performance in sexual activity. There is evidence that, in men with low free testosterone levels, replacement therapy can improve sexual function (Tenover JL 1998; Anderson RA et al 1992; Ahmed SR et al 1988; Davidson JM et al 1982).

Cardiovascular disease and metabolic syndrome. There is a clear relationship between low levels of testosterone and increased incidence of cardiovascular disease, particularly as testosterone level relates to metabolic syndrome (Dobrzycki S et al 2003; Hak AE et al 2002; Zhao SP et al 1998; Jeppesen LL et al 1996). Metabolic syndrome is the combination of abdominal obesity, high blood pressure, insulin resistance, and lipid disorders in the same person. This condition is associated with a high risk of cardiovascular disease. Studies have shown that testosterone administration (500 milligrams [mg] of intramuscular injections) in middle-aged, obese men was able to increase insulin sensitivity (Marin P et al 1992a). These results were confirmed in another study in which testosterone treatment led to reduced insulin resistance (Marin P et al 1992b). Later studies also showed that testosterone administration is helpful in the context of metabolic syndrome (Bhasin S 2003; Boyanov MA et al 2003).

The musculoskeletal system. Bone integrity depends upon a balance between bone formation and bone resorption, which are controlled by multiple factors including estrogen and testosterone (Rucker D et al 2004; Tok EC et al 2004; Valimaki VV et al 2004). One clinical trial has demonstrated that testosterone increases bone mineral density in elderly men (van den Beld AW et al 2000). Testosterone supplementation also has a positive effect on muscle metabolism and strength (Herbst KL et al 2004). The effect is undiminished with age, although older men have a greater incidence of adverse effects.

The Importance of Hormone Testing

When testosterone levels are measured, it is critical to determine the levels of both free and total testosterone to understand the cause of any observed symptoms of deficiency or excess (Pardridge WM 1986).

The Life Extension Foundation believes that a comprehensive battery of tests, along with a careful physical examination, is helpful in detecting hormonal imbalances in aging men. If testing is conducted, it is important to remember that blood levels of both free and total testosterone vary widely among individuals, making it difficult to establish a general threshold for treatment. However, levels are quite consistent within individuals, so it is helpful for men to have multiple tests over time to determine trends and individual thresholds for treatment.

It is also important to note that so-called normal levels of testosterone for older men reflect averages in the current population. The Life Extension Foundation believes that most aging men would prefer not to accept the loss of youthful vigor as normal. Instead, we suggest that a more valid optimal range for all men would be in the upper one-third of the range for men aged 21 to 49 years, and that any supplementation should aim to restore hormone levels to that range.

Finally, during the initial testing, it is imperative to also test estrogen levels. Many of the unwanted effects of male hormone imbalance are actually caused by an elevated estrogen level relative to testosterone level (the estrogen/testosterone ratio).

Using Hormone Replacement Wisely

If a man chooses to pursue hormone testing with the intention of using testosterone supplementation (available orally or as an injection, implant, or skin patch), he should keep several facts and precautions in mind (Rhoden EL et al 2004; Schaeffer EM et al 2004):

The patterns and trends over time of multiple hormone levels (such as free testosterone, total testosterone, and estrogen) determine the specific hormone replacements required.
It is not safe to use large amounts of testosterone in any form.
Hormone replacement should not be initiated without comprehensive testing.
Because of the risk of worsening prostate cancer, careful screening for prostate cancer, including a digital rectal examination and prostate specific antigen (PSA) screening, must be done before starting any hormone replacement program.
Certain conditions are contraindications to hormone replacement (Ebert T et al 2005). Prostate cancer, in particular, can be made worse by increasing available testosterone.
A man who is contemplating taking hormone replacement, whether through a prescription or through supplements, should work closely with a qualified physician to plan a rationale approach to treatment and continued monitoring and screening.
Testosterone Therapies

Synthetic anabolic steroids. Synthetic anabolid steroids sold in the form of patches, creams, pellets, and tablets are chemically different from the testosterone made by the body and do not accomplish the same effect as natural testosterone. These drugs are aimed primarily at the musculoskeletal system and are known to have myriad toxic side effects, including causing serious heart and kidney complications. They are sometimes abused by athletes and bodybuilders who want to build muscle mass. A few of the synthetic testosterone drugs that men should avoid using on a long-term basis are methyltestosterone, danazol, oxandrolone, testosterone propionate, cyclopentanepropionate, and enanthate.

Testosterone patches, creams, pellets and tablets. Scientists learned decades ago how to make the identical testosterone that a mans body produces. However, because natural testosterone could not be patented, drug companies developed all kinds of synthetic testosterone analogues. Currently available recommended natural testosterone drugs include testosterone transdermal patches and testosterone creams, pellets, and sublingual tablets.

Both synthetic testosterone and natural testosterone require a prescription. A physician should prescribe testosterone only after a mans blood tests have verified that he has a testosterone deficiency.

Alternative physicians usually prescribe testosterone creams (available at compounding pharmacies). Conventional physicians are more likely to prescribe testosterone patches. All forms of natural testosterone are the same and all will markedly increase free testosterone in the blood and saliva.

Testosterone and Cholesterol

Millions of aging men have the dual conditions of low testosterone and high cholesterol. Conventional physicians prescribe cholesterol-lowering drugs to reduce cholesterol when in fact the age-related rise in cholesterol may simply be the bodys way of increasing hormone levels by supplying the raw materials from which hormones are made (Dzugan SA et al 2002). Researchers at the Life Extension Foundation have successfully treated high cholesterol levels through a program of bioidentical hormones that restores these hormones to youthful levels, reducing the bodys need to make excess cholesterol. While this approach has received almost no attention outside of alternative health circles, it may prove to be the link between high cholesterol and hormone-related disorders of aging.

Natural Approaches to Boost Testosterone and Suppress Estrogen

Nutrients function by increasing testosterone availability, often by affecting testosterones interaction with SHBG or by decreasing its aromatization (conversion) into estrogen. Natural supplements can complement hormone replacement therapy. For people who choose not to (or should not) use hormone replacement therapy, nutrients can be a vital part of a comprehensive program to reduce the impact of aging on the systems of sex hormone production, regulation, and metabolism. Nutritional therapy also has a role in preventing diseases of the male reproductive tract, such as prostate cancer and benign prostatic hyperplasia (BPH). More specific information on these diseases can be found in the chapters Prostate Cancer and Benign Prostatic Hyperplasia.

The following is a list of nutrients that are part of the Life Extension Foundations comprehensive male hormone modulation program:

Zinc. Zinc is related to testosterone levels. In one animal study, rats subjected to an acute swimming test were either supplemented with zinc or placebo. The study showed that zinc supplementation led to significant increases in testosterone levels and may help in athletic performance (Kaya O et al 2006). Among humans, zinc supplementation in a group of male wrestlers prevented the depletion of testosterone after exertion (Kilic M et al 2006). Additional studies have suggested that zinc is important to the synthesis of testosterone (Ali H et al 2005).

Chrysin. A bioflavonoid called chrysin has shown potential as a natural aromatase inhibitor (Kellis JT Jr et al 1984). Chrysin can be extracted from various plants and is found in high concentrations in honey. Bodybuilders have used it as a testosterone-boosting supplement because, by inhibiting the aromatase enzyme, less testosterone is converted into estrogen. Although chrysin is a known inhibitor of aromatase, in one study it did not result in the expected increase in testosterone levels (Gambelunghe C et al 2003). This may be because of poor intestinal absorption of chrysin (Walle UK et al 1999). The Life Extension Foundation has identified a novel supplement called piperine that increases the bioavailability of chrysin.

Carnitine. Carnitine is an amino acid derivative that may be more active than testosterone in aging men who have sexual dysfunction and depression caused by an androgen deficiency (Cavallini G et al 2004). Both testosterone and carnitine improve sexual desire, sexual satisfaction, and nocturnal penile tumescence, but carnitine is more effective than testosterone in improving erectile function, nocturnal penile tumescence, orgasm, and general sexual well-being. Carnitine was better than testosterone at treating depression (Cavallini G et al 2004).

Muira puama. Muira puama is a South American folk medicine derived from a shrub, Ptychopetalum olacoides, which grows in the Amazon region of Brazil. Also called marapuama and potency wood, it is considered an aphrodisiac and an effective treatment of impotence. Because of its purported libido-enhancing properties, muira puama has been the subject of two published clinical studies by Dr Jacques Waynberg, an eminent medical sexologist and author of 10 books on the subject.

The first study, conducted at the Institute of Sexology in Paris under Dr Waynberg's supervision, consisted of examining the effect of muira puama on 262 men who complained of lack of sexual desire or inability to attain or maintain erection. After receiving 1.5 grams (g)/day of muira puama for 2 weeks, 62 percent of the patients with loss of libido rated the treatment as having a dynamic effect, and 52 percent of patients with erectile dysfunction rated the treatment as beneficial (Wright JV et al 1999).

Dr Waynberg's second study, entitled Male Sexual Asthenia, focused on sexual difficulties associated with asthenia, a deficiency state characterized by fatigue and loss of strength, both symptoms of a testosterone deficiency. The study population consisted of 100 men older than 18 years who complained of impotence and/or loss of libido. A total of 94 men completed the study, and their conditions were evaluated. Muira puama treatment led to significantly increased frequency of intercourse for 66 percent. Of the 46 men who complained of loss of desire, 70 percent reported intensification of libido. The stability of erection during intercourse was restored in 55 percent of patients, and 66 percent of men reported a reduction in fatigue. Other reported beneficial effects included improvement in sleep and morning erections (Waynberg J 1990).

Cruciferous vegetables. Cruciferous vegetables, such as broccoli and cauliflower, contain isothiocyanates and glucosinolates, which act as antioxidants and potent inducers of phase 2 proteins believed to suppress prostate cancer formation (Kris-Etherton PM et al 2002; Talalay P et al 2001).

Quercetin. Wine contains antioxidant polyphenols and quercetin. One study showed that red wine inhibited aromatase. The study attributed this effect to the quercetin and other ingredients (Eng ET et al 2002). In human colon cancer cells, quercetin has been shown to inhibit local synthesis of estrogen by inhibiting aromatase (Fiorelli G et al 1999).

Saw palmetto and nettle extracts. These two supplements are commonly used to reduce symptoms of BPH. In Europe, saw palmetto (Serenoa repens) has been used extensively as a drug for some time. Saw palmettos clinical benefits for prostate enlargement include:

Reduced nocturnal urinary urgency (Boyle P et al 2004).
Increased urinary flow rate (Boyle P et al 2004; Gerber GS et al 2004).
Decreased residual urine volume in the bladder (Giannakopoulos X et al 2002).
Reduced discomfort from urination symptoms (Giannakopoulos X et al 2002; Wilt T et al 2002).
In fact, results of treatment with saw palmetto compare favorably with the prescription drug finasteride, with far fewer adverse effects (Wilt T et al 2002). Similarly, another study compared saw palmetto extract to the prescription drug tamsulosin for 1 year. After the treatment period was over, the symptoms of the patients in both groups had improved, and their PSA scores remained stable. However, the size of the prostate gland decreased only in the group taking saw palmetto, and sexual dysfunction was more common in the group taking tamsulosin. Overall, saw palmetto produced a superior response after only 3 months of treatment, and maintained its superiority (Debruyne F et al 2002). Finally, in a meta-analysis of saw palmetto, researchers found there was an average reduction of 5 points in the International Prostate Symptoms Score (IPSS) across all studies (Boyle P et al 2004).

As with most supplements, it is important to be sure that you are buying the highest quality supplement possible. In the case of saw palmetto, that means supercritical, standardized extracts. Supercritical fluid extraction technology produces an extract of extraordinary purity while leaving behind no solvent residues on the product. The first medicinal herb to benefit from large-scale supercritical fluid extraction was saw palmetto.

While a large number of studies document the benefits of saw palmetto by itself, European physicians frequently prescribe saw palmetto extract that is combined with additional herbs that interfere with other factors involved in prostate enlargement, including nettle root.

Nettle root extract may provide a unique mechanism for increasing levels of free testosterone by binding to SHBG, the globulin that inactivates sex hormones, therefore potentially increasing the amount of unbound, free testosterone (Lichius JJ et al 1997; Schottner M et al 1997; Gansser D et al 1995; Hryb DJ et al 1995; Hirano T et al 1994). Nettle root extract is used extensively, either in combination with saw palmetto or by itself, for relief of BPH symptoms.

In 2005, researchers conducted a randomized, double-blind, placebo-controlled, crossover study of nettle root extract. This is the gold standard of clinical trial formats and is used to rigorously test pharmaceutical drugs before they gain market approval. Almost 600 patients were enrolled in this trial for up to 18 months. At the end of the study, 81 percent of the treated patients experienced significant relief of their symptoms and significant reductions in their IPSS compared with only 16 percent of the control subjects. After the 18-month follow-up, only those patients who continued with the therapy experienced any benefits (Safarinejad MR 2005).

These results were confirmed in another study that examined the effect of saw palmetto combined with nettle root extract on men. Once again, this was a double-blind, placebo-controlled study. In this case, the reduction in IPSS was clearly superior among men receiving saw palmetto and nettle root extract, compared to men receiving placebo (Lopatkin N et al 2005).

Nettle root extract has also shown an affinity for SHBG (Hryb DJ et al 1995). SHBG is closely related to levels of free testosterone and estrogen; most of these hormones travel through the bloodstream bound to SHBG. Any testosterone that is unbound to SHBG is referred to as free testosterone. Studies have shown that men with BPH have elevated levels of SHBG in their prostate gland (Jiang H et al 2004); thus, any nutrient that reduces SHBG levels may also be able to reduce BPH.

Antioxidants. One reason testosterone production may decline is because of oxidative damage directed at the tissues that synthesize testosterone. A Chinese study examined the role of antioxidants in male hormone imbalance or partial androgen deficiency of aging men. The articles authors note that antioxidants (including vitamin A, vitamin E, zinc, and selenium) all support testosterone production (He F et al 2005).

:  
(0)

, 2

, 08 2010 . 18:35 +

2
: gabber
: HRT info part 2

.
. - - . , . . . - . . , , . , , .

, , . , 4 . ( ), . ( ) , .

, - .

, :

. . . .

( ) . , ( ). .

.

( ) -, . , , .

.

1. .

40 :

( , , , , )

()






2. - .

.

:

. . .

() . , . , .

20-49 40 :

LabCorp and Life Extensions Laboratory Hormone Conventional Normal Range Optimal Range
12.4-40 26-40 pg/mL
0-44 15-30 pg/mL
300 1000 600-1000 ng/dl

SmithKline: Hormone Conventional Normal Range Optimal Range
34-194 128-194 pg/mL
0-50 15-30pg/mL
194-833 500-833 ng/dl

Quest Laboratories Hormone Conventional Normal Range Optimal Range
50-210 138-210 pg/mL
0-60 15-30 pg/mL
260-1000 500-1000 ng/dl

, 20-49 . 50 , . , LabCorp - 10.8-24.6, 26-40 50. 50 , . 50.

, . , . . , . , , .

( ), :

/ . / 30 .
. ( ), ( ).

. .

, . , .
. .

3. , .

() ( 30), , , :

1. 80-90 . .

2. 110 () . . .

3. . .

4. , . NSAIDs (, ), , -. , , .

5. . , , .

6. , , 0.5 . .

() , 30 :

1. , .. .

2. 320 saw palmetto ( ) 240 (Urtica dioica). , , . , .

() :

1. . , . / .

2. . . , 30-45 5 , , .

(D) , , . , . . , , 30-45 6 , . , .

, () , - . ( ) ( 30), - / , , .. 40-50 .

***

, , .
. LEF

:  
(0)

, 1

, 08 2010 . 18:33 +

1
: gabber
: HRT info part 1

40 , , . , . , , . , , , .

, , ( , , ) , . , , . , , , , 21 .

, , .

.

, , ( ) . /, . . 54- 59 .

- , , , .. . - , .

., . , . . , , , .

, , . , . , . .

, . . , . .

, , , .
, , . .

.

. , . . , , . . , .

, . - .

. . , 40 .
- . , .

- , , . , . , . . . , , , , .

.

. , , . .

, , . . , ( ), . ( ) . , , . .

, . , ( ). , , . .

.

, , , . .

. , . , .

/ . , , . . , . , . , .

, , , .. . , . , .. .

.

. . , .

. . 68.8% . .
- :

, , .
.
.
( ).
- .

- . ( ) / , / .
, - , .

.

. .

Life Extension 1997 . . , , . , . .

, , . , . , , .

, . . 27 , 5 , 21 . . 21-5 .

- , PSA (- ) . PSA . , . PSA 30-45 . , . , , PSA . .

, 21 5 . , , (saw palmetto), , .

Maximize your Vitality and Potency , . , , , .

, .
, , . . - . () 5--, . , .

, :

- -
( )
3- ,


. - .

, , . , . Life Extension Magazine, 1999.

.

. . - . , . - , . , . .

. 12- (6.9 , 3.9 ). 79% 10% 12 .

, Maximize Your Life and Potency, :








, ,


, - . .

.

, 2 , , - , . , , , .

. , . , . , . .

, ( ), , . . 40 .

.

Eugene Shippen 1998 The Testosterone Syndrome. , . Life Extension Magazine:

-, . , . , , , , , . - , , , , , . - , , .

. . , .

. .

. . . , , . , -. .

, . .

. , . , . . , ( ) 6-12 .

:  
(0)

. ,

, 23 2010 . 21:43 +
: (Jerry Brainum) | : Ironman, #32, 2004

, . : , , . , , , . , .

, . , , . , , .

: . , - , . , . , , , :
30% ; 10% .
, - .
- . ( , , )
- . , . - ( ). , . , 30 .
2000 , .
. . -, ( ), . -, . , , . , , - .
, ( ). , , .
, , - .



- , . - 17- . , , , , ( ), . . , , , , ( ). , - , . : , .

. , , (1).

, . .

(), . , , , , , , , (2).

, , , (3), .

, , , , . - , - . , . - . , , . , , .

, , , , . , , , . - , : , . , , . -2 , .

, , . , , ( ), ( ), , . , , .

- , .

, , . , , (4). , (5).

, : . , , . , , .

, , -, . 4 , 2-3. , - 8 .

, , , . , () , , . , , .

, , . , . : ?

, . , , - , , .

- . 498 38 45 , , , 500 (, ), (1-5- ) 70% , 100 , , (6).

- , , - -3-, , .

, DIM, -3-. , - , .

. , ( ), : 1/500-1/1000 - . , - 2- (7).

, . . , , - , . , , .

, , , , , . , ( ), - , , , (8).

, - .

(16-) , . , 16- 2- . , , (9).

- D- , , , . D- , , , ( ). , D- , , , . D- 200-400 . , , , , .

, ? , , , . , , , , . , , , , , , , . . , , , .
, , , , , , , . - 2 . , , , .

, , . , , , , . . - , , .

, , . , , , , . , -6 , , - - , .

, -3 , - , . -3 , , . 3-6 -3 . , , , , .

. , . , , . , 15-20% , , . , . ( ) (10).

, - . , , , ( ), -2 . , - , . , .

; . - 0,2 . , ( (IRONMAN), MD Cuts MD Cuts), - , , . , , , , .

, , , 500 -2 , (11).

, . , . , , , .

, . , , , . , . , . , . , . Hardgainer.RU

:

OSullivan, A.J., et al. (2001). Efficient fat storage in premenopausal women and in the early pregnancy: a role for estrogen. J Clin Endocrin Metab. 86:4951-4956.
Ballesteros, M., et al. Estrogen inhibits activation of the JAK2/STAT5 pathway by growth hormone. Proceedings 11th International Congress of Endocrinology. 436.
Gonzalez, C., et al. (2002). Effect of treatment with different doses of 17-beta estradiol on the insulin receptor. Life Science. 70:1621-30.
Tarnopolsky, M., et al. (2001). Sex differences in carbohydrate metabolism. Curr Opin Nutr Metabol Care. 4:521-526.
Lamont, L.S., et al. (2001). Gender differences in leucine, but not lysine, kinetics. J Appl Physiol. 91:357-62.
Lucero, J., et al. (2001). Early follicular phase hormone levels in relation to patterns of alcohol, tobacco and coffee use. Fertility and Sterility. 76:723-729.
Xu, X., et al. (1998). Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev. 7:1101-1108.
Nikawa, T., et al. (2002). Effects of a soy protein diet on exercise-induced muscle protein catabolism in rats. Nutrition. 18:490-495.
Haggans, C.J., et al. (1999). Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer. 33:188-95.
Rose, D.P., et al. (1991). High-fiber diet reduces serum estrogen concentrations in premenopausal women. Am J Clin Nutr. 54:520-525.
Stich, V., et al. (2002). Hypocaloric diet reduces exercise-induced A2-adrenergic antilipolytic effect and A2-adrenergic receptor mRNA levels in

:  
(0)

, 22 2010 . 12:56 +
"".



,
,
,
.









,

:

2010 : 35 542 959 7 630 639 566 .

, 1960- - - . , . . 1970-80- , , ( , - ), . Medline 1964 4 , .

(2008 ) .. 100 , . , .. 2005 125 , , , , , . , 2004 , 232 . : 26 . , , . , . , Food and Drug Administration . . 2006 , . , , . , , , . , . 2006 , . 2006 2007 40%, . Pharmexpert. 7 . ( 1,6 , 5,5 , ).



,

: Laboratoires Boiron

2010 : 10 612 431 2 965 309 263 .

, . 1919 , Oscillococci ( , , ). , , , Oscillococci , , . , , , , , , . , Anas Barbariae Hepatis et Cordis Extractum . , -, Anas Barbariae , , , Cairina moschata. -, , , , 10400 , ( 1*1080). , , , . , , , , , , , , - . Pharmexpert 2009 . , , . , , 1992 , , .




,

: Sandoz

2010 : 9 012 447 2 617 403 509 .

, , . . , 1,2*107 , ( ) . -, , . -, , , , 99% , , . , , , , , . () , . , . . , , .

-

,

: Berlin-Chemie

2010 : 24 236 736 2 430 968 386 .

, . , - , , , , , . 2009 , , , . , - - , - . Berlin-Chemie , , : . , , , , , , . , . -, , , , , , . , . , - , . -, , . , , - , , .





:

2010 : 3 914 422 909 499 211 .

, , , , , . ( 8 ), , . , , , , . , . , . 2004 , , . ( 200 . , ) 2000- . , , 2003 . 2006 , 112 . 2008 , , 1,6 . Esquire , , , , . 2010 , , , .





:

2010 : 5 530 972 809 836 329 .

, , ( 8 ), . , , . , , , , , , , , , . . , . , , . , . , , . , . , . , , . 2006 , : , - , . 2010 , , - .










:

2010 : 30 434 899 2 690 230 797 .

, , , , . . , , , ( , , , ), , . , , . , . , . , .

/

,

: Krewel Meuselbach /

2010 : 8 393 029 , 72 551 680 , 867 445 462 . 830 016 553 .

, , , , 1963 , . - ( 3%) (1,12%) , . , , . , . , , , . . 2008 , , , , , , - .



,

: Ebewe

2010 : 1 302 958 1 315 690 225 .

, , , (, ), ( ) . 2010 Cochrane Collaboration, , , , . , . , . : 146 ... . 6 78 , , 6 68 , . .



, ,

: UCB Pharma

2010 : 1 346 264 387 435 930 .

20 , , , , . , . Medline 1990- , , . PASS (Piracetam in Acute Stroke Study) 2001 . . FDA (). , . 2008 , (1990- . Esquire) . . , , , . . , 2006 , : 18 , , , , , . : , .






: , , ,

2010 : 12 265 705 396 485 699 .

2- , . taurus (), . , . 4% , , , , . : , , Medline , (Thimons J.J., Hansen D., Nolfi J. Understanding taurine and its possible role in ocular health // Optometric Management. April, 2004). Complete MoisturePlus, . , , , , ... . , www.alibaba.com.

/



:

2010 : 65 803 , 195 868 , 11 568 802 . 52 973 410 .

, () . . () ( ) , , , - , , , , , , , . Medline 268 , (253 ), (, , ) . 2010 . , , , , , , , . , . , . , , , , , , .



,

:

2010 : 467 044 220 255 370 .

, , , 1980- . , 2008 . , , () 2008- , . , . 2008 - , , . , . 2009 : , . /H1N1 . . .



, , ,

:

2010 : 692 3 643 474 .

- . , , . , , . , . , , , -, , -, . , , . - , -, , . 2007 . - , , . , . , . , - . , , DNI.


, - , , , .

:  
(0)

, 22 2010 . 12:39 +


.

, .

!
, , , , .

, , , :

-
-
-
-
-
-
-
-
-

- , , . - , .
, , , , .

, , , ( ) !

:  

 : [3] 2 1